Ashish Saxena, MD, PhD, Weill Cornell Medical College

Articles

Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLC

April 19th 2024

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

Takeaways and Considerations for the Future in the Treatment of SCLC

July 5th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the possibility of expanding the use of supportive care regimens to reduce the effects of myelosuppression in patients with SCLC.

Practical Considerations Regarding the Incorporation of Supportive Care Into Practice

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, consider the broader impact of supportive care on cost burden and quality of life and share scenarios in which supportive care is most appropriate.

Quality of Life and Patient-Reported Outcome Measures in SCLC Treatment

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.

The Role of Supportive Care in the Management of Myelosuppression in Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, talk about factors to consider when weighing the risk/benefit ratio associated with the use of cyclin-dependent kinase 4/6 inhibition.

Challenges in the Management of Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the impact of chemotherapy-induced myelosuppression on patients with SCLC.

Dr. Saxena on a Challenging Case of NSCLC

November 8th 2021

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Dr. Saxena on the Future of Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Saxena on Available Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Saxena on the Importance of Initial Treatment Selection in ALK+ NSCLC

January 24th 2020

Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.

Dr. Saxena on the Importance of Biomarker Testing in ALK+ NSCLC

January 8th 2020

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

Dr. Saxena on Treatment Options in ALK+ NSCLC

December 13th 2019

Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.